Research
Hormonal
Using ambulatory blood pressure monitoring (ABPM) instead of clinic-based measurements reveals a stronger and more consistent cardiovascular benefit from GLP-1RA therapy.
If you are on GLP-1RA therapy, ask your doctor about using ambulatory blood pressure monitoring (ABPM). It may provide a more accurate assessment of your cardiovascular risk and the effectiveness of your treatment compared to standard clinic blood pressure readings.
GoodQualifiesMEDIUM confidence
In contrast, trials that used ambulatory or nocturnal BP monitoring (e.g., SURPASS-4, SURMOUNT-OSA, FLOW) demonstrated a more pronounced and consistent reduction in MACE, with a pooled HR of 0.82 (95% CI: 0.75–0.89; p < 0.00001) and no heterogeneity (I² = 0%).
Why this rating
Based on subgroup analysis of RCTs, though limited by the small number of trials using ABPM.
Source
Ambulatory BP and Weight Reduction as Predictors of GLP-1RA CV Benefit
Nicolás Renna et al. · medRxiv · 2025
DOI 10.1101/2025.06.12.25329536
Meta-analysis · 10 studies
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →